Podcasts about Genentech

In this episode, Ray Cochrane digs into Anthropic’s Model Hardware Standard. It is a shared driver that lets an AI agent run real lab equipment, from pipetting robots to the lasers inside a quantum computer. He also covers OpenAI’s builder’s guide to GPT-5.6, Google’s new Expert Intelligence book feature, Apple’s M5 Ultra Mac Studio, and a judge’s order forcing Google to stop hiding rival app stores. Finally, he weighs in on Apple’s proposed 15 percent link-out fee, Meta’s Australia numbers, the White House deputizing private hackers, and why rivers obey a 1957 math rule. – Want to start a podcast? Its easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens with a quick personal update. He is hunting for tickets to Michigan for his dad’s anniversary, and he has been learning Blender and Godot on the side, mostly modeling and blocking out levels. Consequently, he asks listeners for advice on starting a big game project, and he plans to record his progress, maybe as a time lapse. Then it is straight into the featured story. Anthropic’s Model Hardware Standard: A Driver for the Physical World The featured story comes from Anthropic, which opened a research preview of the Model Hardware Standard, or MHS. Cochrane frames it as the other side of the question NVIDIA’s world models raised two weeks ago: when do AI agents start touching actual machines? A typical lab runs a microscope, a liquid handler, a robotic arm, and a plate reader, each from a different vendor with its own control software. One Janelia researcher in the post launches seven programs in three languages just to start an experiment. Anthropic says wiring a setup like that takes weeks or months of specialist work. MHS is a driver, the same kind of translation layer a printer uses, except every device gets described with a tiny set of commands like read and write. Devices announce themselves on the network. A plain-English reference file then records what each machine measures, what can be adjusted, and which safety limits get enforced no matter what the agent asks. Agents then reach the hardware through the Model Context Protocol, the command line, or plain code. Cochrane sees the same move the industry keeps making, from coding harnesses to RSS and JSON: agree on a standard and let everyone build against it. In fact, he calls MHS the hardware version of MCP. The partner results carry the segment. QuEra builds quantum computers from individual atoms held by lasers that must hold their frequency to about one part in a trillion. A four-person team spent months on a relock script that worked 58 percent of the time. However, four copies of Claude iterating overnight through MHS produced a decision-tree script that recovers the laser in about six seconds, and it passed 99.3 percent of 700 blind trials. Carnegie Mellon wrote MHS drivers for four instruments across three incompatible computers in about eight hours, then ran dose-response experiments three times faster and blocked all six deliberately induced faults. Genentech, meanwhile, showed the limits. Claude used the same pump speed for water, a foamy protein solution, and a human had to explain that the bubbles were a physics problem. That gap in physical intuition is what sticks with Cochrane. He doubts it will change soon, and he suspects the fix will arrive as sub-agents or sub-models that judge a request against an expected outcome. He also connects MHS to a video of racing robots that never learned to stop at the finish line. What happens, he wonders, once they can read a distance sensor through a shared standard? Still, he calls the announcement a fantastic read and points listeners to the full article. Sponsor: GoDaddy Economy hosting $6.99/month, WordPress hosting $12.99/month, domains $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. GPT-5.6 Does the Same Work for a Fraction of the Cost OpenAI’s builder’s guide to GPT-5.6 leads the headlines. Cochrane recaps the three tiers from episode 1870, Sol, Terra, and Luna, plus the separate dial for reasoning effort. On BrowseComp, a benchmark for digging up obscure facts on the web, the old GPT-5.5 flagship scored about 84 percent on a run that cost 33 dollars three months ago. Luna now matches that score for a dollar thirty-three, and OpenAI has since cut Luna’s price another 80 percent. Browser Use reports Luna finishing 78 percent of its hardest browser tasks for about 14 dollars, against 80 percent for roughly 235 dollars from the best available model. The guide’s other big addition is a multi-agent beta flag. It lets the model handling a request spawn parallel helper agents that report back to a root agent inside a single API call. However, Cochrane is unimpressed by the timing. He has been running that pattern in Claude Code for months, so he sees OpenAI copying a workflow other companies already ship rather than inventing its own. Along the way, he plugs Claude Code’s remote-control sessions, which let him send prompts from his phone to a terminal session at home. Google Lets Gemini Read the Books You Actually Bought Google launched Expert Intelligence, a name Cochrane calls quite the reach. The feature lets you drop a book you bought on Google Play Books into Gemini Notebook, formerly NotebookLM, and ask questions answered only from that book, with citations. Cochrane sees real power here for students, since he once used NotebookLM to organize scattered course PDFs. Additionally, publishers get a cut, which he calls a far better deal than the wholesale scraping of books that trained earlier models. Nevertheless, he asks who loses out, because a paid publisher does not automatically mean a paid author. He floats the same idea for artists, even a penny per use, then admits that may be too idealistic. Apple’s M5 Ultra Mac Studio Is Built to Run Big Models at Home Back in episode 1861, when Apple killed the Mac Pro, an M5 Ultra Mac Studio was expected later this year. Now it is here. The M5 Ultra brings up to a 36-core CPU, an 80-core GPU, and 512GB of unified memory moving 1.2 terabytes per second. Apple claims up to 4.3 times the AI performance of the M3 Ultra. Thunderbolt 5 can also cluster four machines into one memory pool for up to three times faster inference. The M5 Max model starts at $2,499 and the Ultra at $5,499, with shipping on September 22 and the 512GB configuration arriving in late October. Cochrane finds the clustering pitch ridiculous at that price, but he invites anyone who spends the money to report back. Apple Opens a Manufacturing School in Houston Apple also opened a 20,000-square-foot Advanced Manufacturing Center in Houston. It offers free classes for small and midsize manufacturers, from circuit board design to hands-on time on a scaled-down production line, with college students joining later. Cochrane calls it a solid step in the bring-manufacturing-home movement. The bigger story is the campus itself, which builds Apple’s AI servers and will add the first US-assembled Mac mini line later this year. That ties back to the Mac mini shortage that followed the OpenClaw rush, when Tim Cook warned of months-long waits. Cult of Mac was still reporting four-month waits in late July. However, Cook blamed chip supply rather than assembly, so Cochrane is not counting on relief just yet. Amazon EC2 Turns Twenty Amazon EC2 turned twenty this week, which Cochrane admits makes him feel old. The 2006 beta offered one server size in one region for ten cents an hour. Each came with a 1.7 gigahertz Xeon and under two gigabytes of memory, and accounts were capped at twenty servers. Today AWS offers more than 1,200 instance types across 39 regions. Consequently, Cochrane credits the company with turning that tiny product into the backbone of cloud and AI computing. Intel Gamer Days: Two Free Games, With Fine Print Intel Gamer Days runs through September 13. Buy a qualifying Core Ultra Series 2 or 14th Gen desktop chip, a Core Ultra Series 3 laptop, or an Arc graphics card. In return you get Star Wars: Galactic Racer plus the Tomb Raider: Legacy of Atlantis remake. GamesRadar values the pair at about 120 dollars. However, neither game is out yet, and codes must be redeemed by October 31 even though the Tomb Raider remake ships in February. Cochrane calls that awful, but he still tells qualifying buyers to claim the deal early. Note that 13th Gen chips do not qualify. Judge Orders Google to Stop Hiding Rival App Stores A jury found Google’s Android app monopoly illegal in late 2023, and Judge James Donato ordered rival stores into the Play Store in 2024. On August 13, Epic’s lawyer demonstrated that searching Play for “store for apps” returned Walmart instead of any app store. Donato called that “not acceptable” and ordered three fixes within a week. Searches must surface third-party stores, listings need a plain install button, and the “are you looking for” interstitial has to go. Cochrane welcomes the monopoly being chipped away, but he notes that a controlling entity still sits atop every app store. In his view, community hubs like app stores and social media need a public infrastructure layer. He suspects governments skip that investment because companies already run the services, while selling your data. Apple Wants 15 Percent of Purchases Outside Its Store The other half of the Epic saga is Apple’s proposed link-out commission. After the 2021 anti-steering injunction, Apple charged 27 percent on purchases made through external links. A judge held it in contempt last year, and the Ninth Circuit then allowed a fee limited to the cost of running the system. Judge Yvonne Gonzalez Rogers refused to wait for the Supreme Court, writing that “further delay is unwarranted.” Apple filed 15 percent for standard apps, 10 percent for subscription renewals and partner programs, and 5 percent for small businesses. It also conceded the rate would be “essentially zero” under the appeals court’s cost yardstick. Since Apple has charged nothing on link-outs since the contempt ruling, Cochrane sees this as a raise. He calls a cut on purchases made on a developer’s own website disturbing. He also recalls reading about the size of Uber’s payments to Apple, and he questions whether that kind of percentage is sustainable for companies without funding. Meta Says It Has Cut Off 750,000 Australian Kids Meta reported locking out more than 750,000 Facebook and Instagram accounts in Australia by the end of June under the country’s under-16 social media law. Over 500,000 of those were removed before the law even took effect. Detection relies mostly on AI scanning posts and bios for tells like birthday messages, plus user reports and blocks on re-registration. However, the post gives no count of mistaken removals or appeals, and the regulator’s early data shows under-16 usage falling only from about 86 to 81 percent. Meta wants a single age signal at the operating system or app store level, and Cochrane agrees completely. He connects it to the MHS idea from the top of the show: platforms need a standard flag to reference instead of guessing. The White House Deputizes Private Hackers Earlier this month the White House signed a National Security Presidential Memorandum that lets vetted private security firms run surveillance and disruption operations against overseas criminal groups. The Justice Department and Homeland Security hold the contracts and oversee the work. Firms need a proven track record, vetted staff, and a bond of at least $1 million, and must submit operating procedures within 60 days. Cochrane finds the measure aggressive in a good way and hopes it deters attacks on innocents. Still, he takes Kevin Beaumont’s warning seriously that the private security industry profits from ransomware existing. He compares it to the old Head and Shoulders myth: why solve the problem that drives your revenue? A Weather Satellite Watched the Eclipse Shadow Cross Europe Cochrane skips the readout on this one and simply sends listeners to ESA’s site. The MTG-I1 weather satellite captured the Moon’s shadow sweeping across Europe during the August 12 eclipse. Watching a shadow cross an entire continent, he says, was a first for him. Additionally, it leaves him excited about the research happening beyond the planet. Rivers, Deltas, and the Number 0.6 Quanta Magazine explains Hack’s law, which John Hack discovered in 1957 while measuring streams in Virginia and Maryland. A stream’s length tracks its drainage area raised to the power of 0.6, regardless of the rock underneath, and satellite data later confirmed it worldwide. Computer models in the 1990s showed why. Channels that capture extra runoff cut deeper and steal from their neighbors until the network settles into the arrangement that wastes the least energy. Now a University of Texas Rio Grande Valley team has found the same 0.6 exponent in river deltas, which spread water out rather than gathering it. Nobody knows why yet, and Cochrane calls it a really cool read. Sugar Helped Grow the Human Brain, Too A new paper in Science, co-authored by Jennie Brand-Miller at the University of Sydney, adds a third ingredient to the story of early human brain growth. Alongside meat and cooking, natural sugars from ripe fruit and honey may have fueled it too. The brain is about two percent of body weight but burns twenty percent of resting energy. It runs on glucose, which meat and marrow barely supply and raw starch cannot release without fire. The team modeled ancestral diets from a chimp-like baseline through Homo erectus and concluded that the earliest hominins may have drawn over 65 percent of their energy from natural sugars. Cochrane stresses that it is a model, not fossils, and notes that paleoanthropologist Marina Lozano thinks the authors place widespread cooking too early. Still, he loves this kind of deep research. Retracing the steps to our own intelligence, he suggests, could hint at what it takes for intelligent life to develop at all. A Brain Rhythm That Tells Doctors Where to Aim Finally, Science Daily covered a University of Cologne study on deep brain stimulation. That is the implanted-electrode treatment that eases Parkinson’s tremors for some patients but not others. Andreas Horn’s team recorded from 50 patients using both the implanted electrodes and an external magnetic scanner. They identified a circuit between the electrode’s target and the frontal cortex that oscillates at 20 to 35 cycles per second. Stronger coupling there predicted bigger improvement after surgery, though the study, published in Brain, shows correlation rather than cause. First author Bahne Bahners hopes the finding helps tune DBS more precisely, especially for patients who have not responded well. Cochrane half-jokingly asks whether MHS might one day drive those electrodes, and he calls brain disorders the hardest thing in the body to treat. Cochrane wraps with housekeeping: become a GNC Insider at geeknewscentral.com/insider, email geeknews@gmail.com with questions or comments, subscribe to the newsletter, and grab a modern podcast app at podcastapps.com. He thanks GoDaddy for over twenty years of keeping the show on the air, promises to catch everyone next Monday, and wishes listeners a great night. The post Eyes, Hands, and a Sense of Timing #1874 appeared first on Geek News Central.

Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: BMS Chooses Houston for $2.3B Manufacturing FacilityBy Alex Philippidis, GEN Edge, Aug 10, 2026Next 10 U.S. Biopharma ClustersBy Alex Philippidis, GEN, Aug 12, 2026Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI MapBy Alex Philippidis, GEN Edge, Aug 5, 2026COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVIDGEN, Aug 5, 2026Trump's Treatments: Regeneron's Antibodies and Gilead's Remdesivir ExplainedBy Alex Philippidis, GEN, Oct 5, 2020Lessons from the COVID Crisis: An Interview with Peter HotezBy Alex Philippidis, GEN Edge, Oct 19, 2022How to Conquer Coronavirus: Top 35 Treatments in DevelopmentBy Alex Philippidis, GEN, March 2, 2020Candida auris Persists in Hair Follicles, Hijacks Immune SignalingGEN, August 10, 2026The State of Biotech SummitSeptember 23, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026Subscribe to GEN's newsletters Hosted on Acast. See acast.com/privacy for more information.

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.

As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and caregiver experience. In this episode, CANCER BUZZ explores how it feels physically and emotionally for patients to begin and continue BsAb therapy. Grounded in real-world insights, this discussion highlights the logistical and emotional challenges that arise during the step-up period and early treatment phases and identifies opportunities for care teams to better support patients throughout their journey.  In partnership with HOPA and APSHO. This program was made possible with support from Johnson & Johnson and Genentech. Guest:  Leslie Mader, RN, BSN, OCN  Patient Care Coordinator, Bispecific Drug Therapy and IEC Therapy, Hematology/Stem Cell Transplant  Vanderbilt Ingram Cancer Center "It decreased the amount of time they had to be in the clinic, you know, because a lot of these people we're getting them back to their regular lives where they can work, they can go to you know continue on with life. So anything that we can give that's in an injection, and anything that's targeted to decrease systemic reactions is better for the patient."  - Leslie Mader "They think, oh, this is great. I'm going to get through it with no problems. And then they get dose three or dose four, and they're like crap. You know, they get discouraged. But usually, you know, we have emergency drugs that we give them dexamethasone, and it usually resolves quickly."  - Lesie Mader Resources: A Blueprint for Successful Integration of Bispecific Antibodies   Delivery Models for Administering T-Cell-Engaging Bispecific Antibodies  Delivering T-Cell-Engaging Bispecific Antibodies: Frequently Asked Questions (FAQ) ACCC Office Hours Recording - Bispecific Antibodies: One BiTE at a Time     Bispecific Antibodies Checklist for Community Providers Using Bispecific Antibodies in Community Practice: Challenge and Opportunities Expanding Access to Cellular and Bispecific Therapies: Considerations and Recommendations   

This is At the Table, the Food Allergy Podcast—a show about food, connection, and living with food allergies. Each episode, we pull up a chair to a different table—from date nights to tables abroad—and discuss navigating each moment while still eating safely. Because living with food allergies isn’t just about what you can’t eat; it’s about still having your seat at the table. This show is brought to you in partnership with Genentech and Novartis. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after accidentally eating one or more foods to which you are allergic. While taking XOLAIR you should continue to avoid all foods to which you are allergic. It is not known if XOLAIR is safe and effective in people with food allergy under 1 year of age. XOLAIR should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. What is the most important information I should know about XOLAIR? Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction: wheezing, shortness of breath, cough, chest tightness, or trouble breathing low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom” flushing, itching, hives, or feeling warm swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction. Please see the full Prescribing Information for additional safety information, including Boxed Warning, and Medication Guide by visiting bit.ly/XOLPISee omnystudio.com/listener for privacy information.

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. ·       How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 ·       How can we effectively onboard APPs? 10:24 ·       Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 ·       What models have worked well for deploying APPs into GI practices? 24:32 ·       What strategies are most effective for APP retention? 29:07 ·       How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc.  Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.

Something happens. The tire goes flat, the layoff comes, test results come back. And then a sentence starts running in the back of your head. That shouldn't have happened. I should weigh less. They shouldn't have fired me. You barely register it. It plays like a radio in another room, and it produces a feeling, and the feeling produces a behavior, and the behavior produces the day you are having. The stress paradox is that the thought causing you the most pain is also the one that feels most obviously true. Of course they shouldn't have fired me. The belief feels like clear sight rather than distortion, and it feels useful, like it is the thing that will finally motivate change. It almost never is.  Treating stress as a condition to be managed rather than a belief or thought to be examined leaves it running. My guest is Andy Bernstein. Andy is the creator of Active Insight and the founder of the Resilience Academy. He is the author of Breaking the Stress Cycle, and he has taught at Wharton Executive Education since 2007, where his sessions have been audience favorites for thousands of leaders. His corporate clients include Merrill Lynch, Morgan Stanley, Johnson & Johnson, Google, Coca-Cola, and Genentech.  Andy built a process for dealing with stress that is seven steps, done on paper. You do not lie on a couch. You do not say a word. In this conversation, he walks through all seven steps live, twice. Challenging the way other people think is something we all do constantly. Challenging your own thinking is something we rarely do.  Some highlights from the episode: 03:32 Losing his father at 14 and his sister at 16  06:00 Byron Katie, The Work, and a job he never meant to leave  08:26 Active Insight  11:07 Field-testing  14:51 Where our idea of stress came from  19:25 Bears, war zones, and the adaptive exception  24:41 "Should" as the argument with reality  29:33 The seven steps, walked through live  30:43 What is negation? 36:50 Running the process on "they shouldn't have fired me"  39:19 The showdown with yourself  43:37 Time doesn't heal wounds. Insight does.  44:34 The Grant Study and not pushing love away  47:00 Doing it in your head, and when that isn't enough  50:47 Won't I become a doormat?  51:09 Flow, not stress  53:49 The psychology of subtraction Enjoy! For show notes and more, visit larryweeks.com/podcasts  

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with Erin Gillaspie, MD, MPH, and Laurie Matt-Amaral, MD, MPH, about navigating challenges as women in oncology, investing in relationships and more. ·       Gillaspie and Matt-Amaral share their journeys within their fields. 2:37 ·       Have you ever experienced imposter syndrome? 9:26 ·       How did you navigate moments when it felt like you had hit a wall? 10:36 ·       How have you balanced family life and your career? 21:25 ·       If you had to give two or three tips for up-and-coming women physicians, what would they be? 30:07 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Gillaspie can be reached at eringillaspie@creighton.edu or on Instagram @dreringillaspie. Matt-Amaral can be reached at mattaml@ccf.org. Jain reports no relevant financial disclosures. Gillaspie reports consulting or speakers bureau roles with and/or travel, accommodations and expenses from AstraZeneca, Bristol Myers Squibb, Genentech, Intuitive Surgical and Merck. Matt-Amaral reports research funding to her institution from Agendia.

How do you help others truly understand what it's like to live with food allergies? Through the power of storytelling. In this episode, we explore Food Allergies in the City, a new micro-drama series inspired by the real experiences of young adults living with food allergies. FAACT helped bring authentic community voices to the project, and we're joined by Del Conyers, Genentech's Director of Patient Advocacy Relations, and FAACT Director of Marketing, Lisa Horne, to discuss how storytelling can educate, inspire, and raise food allergy awareness in a whole new way. Resources to keep you in the know:Food Allergies in the City: Watch the 4-part, micro-drama seriesYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: GenentechThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Lefkowitz was told in 1973 that hormone receptors were a figment of his imagination. The work that proved otherwise became the molecular foundation of GPCR pharmacology.Nobel laureate Robert Lefkowitz traces the full arc of GPCR discovery — from developing the first radioligand for the beta-adrenergic receptor to purifying it, cloning it, and watching a sequencing run reveal structural homology with rhodopsin that nobody in the field had predicted. That 1986 paper established the GPCR superfamily. The same system yielded the GRK family and the beta-arrestins. This conversation is also about the human architecture behind that science: how a Vietnam War draft assignment in 1968 redirected a physician toward a question the field wasn't sure was real, what 18 months of unbroken failure at the NIH taught him about research, and why he argues that if 50% of your experiments succeed, you are not working on hard enough problems.How a Vietnam War draft sent a physician to the NIH — and gave rise to 50 years of GPCR receptor pharmacologyWhy Lefkowitz chose the beta-adrenergic system, and why he considers it the smartest scientific decision of his careerThe cloning race against Genentech: the "stupid idea" that worked and the intronless gene that ended the competitionHigh output vs. low output failure — how to find the research territory between trivial problems and intractable onesWhat the Nobel call at 5 AM actually felt like: not jubilation, but relief — and a tear when he learned who he'd share it withDr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Membership & Pricing: https://www.ecosystem.drgpcr.com/university-pricingWeekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PFX865. CME/MOC/AAPA/IPCE credit will be available until June 27, 2027.New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Serin Silva is an intuitive strategic advisor and executive coach who helps powerhouse women move from stuck to strategic growth. After two decades leading transformation as a VP at Fortune 500 companies, including taking Williams-Sonoma to half a billion in sales and launching Hearst Corporation's first digital division, Serin now guides CEOs and executives to make clear, confident, and energetically aligned decisions in the moments that matter most. Her work blends sharp business strategy with intuitive insight, a rare combination that's helped clients scale from $10M to $25M, land CEO roles, and transform from self-doubt to self-belief. Serin helps high-achieving women recalibrate how they lead, turning overwhelm into clarity and performance into purpose. Her clients include leaders from Apple, Patreon, Airbnb, Genentech, UCLA, and Microsoft.  

Most clinical research treats patients like data points. What gets lost when researchers stop listening to the people they study, and what does it cost the science itself? Niharika Singh is a biomedical engineer and pre-medical student with research experience at Genentech, Abbott, AstraZeneca, and the Keck School of Medicine, and a global ambassador with the United Nations SURGhub. She discusses the KevinMD article "Patient involvement transforms modern clinical research." You will hear the difference between treating a patient as a data set, engaging them as a collaborator, and inviting their emotional and lived experience into the study design. She walks through the Tiger Project hernia training across India and Ghana, what medical device design verification taught her about surgical research, and why AI in medicine is making patient voice harder to hear. You will hear a research methodology that treats the patient's voice as data worth collecting, and a case for defending human connection as AI changes how medicine is practiced. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Moderna's mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment, though the agency did flag certain data gaps for advisors to review.Biotech IPOs are off the charts—literally. This past month has seen not one but two record-setting public debuts. First there was Kailera Therapeutics, which hit the market with $625 million in April, outpacing Moderna's 2018 IPO of $600 million. And now we have Parabilis Medicines, which last week dethroned Kailera as the largest biotech IPO of all time, with $670 million.Meanwhile, the number of employees laid off spiked by almost 50% year-over-year in May, though that jump is mostly due to significant cuts at Takeda and BioNTech.Genentech also made a big change last week.Eli Lilly continued its dealmaking spree with AlzeCure, striking a licensing agreement worth up to $1 billion centering on a small-molecule asset for Alzheimer's disease. But the bigger Lilly news in the past week was clinical results that show promise for the pharma's $2.3 billion acquisition of Ajax Therapeutics in April.Earlier this month, the FDA held a public session to glean feedback regarding the Commissioner's National Priority Voucher program, in which several groups called for a temporary pause to the pilot, citing concerns about transparency and political involvement. While the future of that program hangs in the balance, two voucher holders got updates this week. First, Sanofi's diabetes drug Tzield was greenlit for older kids and teenagers, though it's unclear whether a voucher was associated with the approval. Meanwhile, Disc Medicine's rejected rare disease drug bitopertin appears to be back on track, with the biotech announcing last week that the FDA will allow its current Phase 3 trial to support another regulatory filing.

Send us Fan MailWe're living through the fastest technological acceleration in human history.Every week brings a new AI model, a new productivity tool, and a new prediction that everything is about to change forever.And yet somehow, most people feel less focused, less certain, and more overwhelmed than ever.In this episode of FUTUREPROOF., I sit down with Fredric Marshall, author of THRIVE: The Antidote to Future Shock, to explore a possibility we don't talk about enough:What if the biggest risk of AI isn't that it replaces humans?What if it's that it exhausts them?Fred has spent decades helping organizations like Apple, Pfizer, and Genentech navigate periods of intense change. His argument is that most organizations aren't suffering from a technology problem. They're suffering from an attention problem.We're surrounded by tools designed to save time, yet nobody seems to have any.We have more information than ever, yet many leaders feel less certain.And we keep calling it a productivity problem when it may actually be a human capacity problem.We discuss: Why "future shock" may be the defining leadership challenge of the AI era  How AI can reduce friction—or quietly create more of it  Why burnout is often a systems problem disguised as a personal one  The hidden cost of constant context switching  Why clarity may become more valuable than speed  How leaders can separate signal from noise  What it actually means to thrive during exponential change Because if every problem gets solved with another app, another dashboard, or another AI assistant...At some point, someone has to manage all those solutions.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EQG865. CME/MOC/AAPA credit will be available until June 17, 2027.Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

In this episode of Mind the Meds, Erica Marini, PharmD, highlights information from the European Stroke Organization Conference include encouraging data on asundexian(Bayer), a factor XIa inhibitor showing reduced recurrent ischemic stroke risk without increased bleeding, as well as positive results from three trials of tirofiban in acute ischemic stroke settings. On the multiple sclerosis (MS) front, Marini covers the FDA approval of ocrelizumab (Ocrevus; Genentech) for pediatric relapsing-remitting MS in children 10 and older, a new study supporting early use of high-efficacy agents in pediatric MS, and 2 Lancet publications on ocrelizumab — one examining higher weight-adjusted dosing (which did not improve disability progression) and one confirming benefit in a broader primary progressive MS population. She also briefly discusses PADOVA (NCT04777331), a phase 2b trial of prasinezumab in early Parkinson's disease, which failed to meet its primary end point.The bulk of the episode is a discussion with guest Millad Sobhanian, PharmD, BCPS, clinical pharmacy specialist in neurology at the University of Maryland, focused on Alzheimer disease. They cover dextromethorphan/bupropion (Auvelity; Axsome Therapeutics), newly approved in April 2026 for agitation associated with Alzheimer dementia. Sobhanian walks through key safety considerations—including additive NMDA antagonism if combined with memantine, cardiovascular risks from the bupropion component, and the ever-present black box warning on antipsychotics in dementia patients—while both note that the efficacy data, though statistically significant, shows modest clinical effect sizes compared to the threshold for meaningful within-patient change.The conversation then turns to lecanemab's subcutaneous initiation formulation (Leqembi Iqlik; Eisai, Biogen), whose FDA decision has been delayed to about August 2026 as regulators seek more data on bioavailability and ARIA monitoring in the at-home setting. Sobhanian shares his real-world perspective on anti-amyloid therapy, describing a patient population that is typically early-stage, high-functioning, and has a mean age of about 60 to 70 years, and emphasizing the pharmacist's role in expectation-setting around the modest but potentially cumulative slowing of cognitive decline. The episode closes with a thorough discussion of the April 2026 Cochrane review on amyloid-targeting monoclonal antibodies, which both Marini and Sobhanian find overly broad in its conclusions. They note limitations such as the inclusion of withdrawn agents like aducanumab (Aduhelm; Biogen), heterogeneous inclusion criteria across trials, and an 18-month study horizon that may be too short to capture the full benefit suggested by longer-term open-label extension data.Key Takeaways:1. New options for Alzheimer's agitation exist, but fit carefully into the treatment algorithm. Dextromethorphan/bupropion offers a novel NMDA-based mechanism for treating agitation in Alzheimer dementia, but its clinical effect size is modest, and it carries meaningful safety considerations—particularly around the bupropion component in elderly patients. Like all pharmacologic options in this space, it remains a later-line choice after nonpharmacologic interventions have been exhausted, and medication reconciliation is critical given its interaction potential with memantine and CYP2D6 inhibitors.2. Anti-amyloid therapies are imperfect but not ready to be written off. The April 2026 Cochrane review drew significant attention with its conclusion that anti-amyloid monoclonal antibodies produce only trivial cognitive benefits, but its findings are limited by the inclusion of older, withdrawn agents, heterogeneous trial populations, and an 18-month time horizon that may be too short to capture the full trajectory of benefit.3. The pharmacist's role in anti-amyloid therapy goes well beyond dispensing. As illustrated by Sobhanian's practice at the University of Maryland, clinical pharmacists embedded in neurology clinics play a critical role in patient selection, expectation-setting, ARIA counseling, and informed decision-making for patients considering anti-amyloid therapy—a complex, high-stakes treatment decision that these patients and their caregivers should never be navigating alone.

Kevin Mack, the new president of Via Licensing Alliance, joins Eli for the Clause 8 season finale.Kevin talks about Via's plans to build its next patent pools around "de facto" standards — technology the market adopted on its own, with no standards body behind it — which would push collaborative licensing into territory it has never touched. Mack also takes a hard look at the royalty-free models spreading through tech and AI, from AV1 to the new Shared AI License Foundation (SAIL), argues that "free" rarely stays free, and explains why he's optimistic about where the patent system is heading.Kevin and Eli also discuss:*Via's model and the "tipping point" that turns a pool from a few licensors into thousands of licensees*"De facto" standards: pooling patents for technology no standards body ever blessed*Leadership turnover at Via, the HEVC pool's move to Access Advance, and a new strategy-and-growth group*The push into semiconductors, including a new DRAM memory program*AV1, SAIL, and why Mack thinks royalty-free rarely stays free*Whether AI patents are as "foundational" as advertised — and why "AI is not new"*Efficient infringement, patents as property rights, and why companies ultimately take a license*The mood out of Via's Rome summit and a US patent system tilting back toward ownersNotable names, companies & standardsPeople: Kevin Mack (president, Via Licensing Alliance); Heath Hoglund (former Via president); John Amster (Jamster Capital; RPX co-founder)Organizations: Via Licensing Alliance (Via LA), MPEG LA, Dolby, Access Advance, Alliance for Open Media, Shared AI License Foundation (SAIL), WIPO (PatentScope), DOJ, USPTOSAIL founders / board (public): Anthropic, Genentech, IBM, Meta, Microsoft; board observers eBay and TD Bank Group; members include Block and FigmaStandards & technologies: AAC, AVC (H.264), HEVC (H.265), AV1, MPEG-2, Qi wireless charging, DRAM memory, SEP / FRANDDisclaimer This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.voiceofip.com

Purti Kanodia Talks Real-World AI Applications. On this episode of OWA Talks, Purti shares a practical, no-hype approach to building AI fluency. Join us as we get beyond the ‘theory' and talk implementation. If you're curious about AI but overwhelmed, this one's for you.About the guest:Purti Kanodia is a fractional AI transformation leader and founder of Clarity Prompts, an AI consulting firm and weekly newsletter that helps executives and senior leaders build AI fluency and lead practical, responsible AI adoption across their organizations.With nearly two decades of experience across optical retail, employer healthcare, management consulting, and biopharma, Purti has worked with companies including National Vision, Crossover Health, Slalom Consulting, and Genentech, always at the intersection of technology, business strategy, and human change. At National Vision, she led the launch of Toku BioAge, the first AI-based retinal imaging wellness product in US optical retail. Earlier at Slalom Consulting, she spent two years in Ophthalmology designing product strategy for AI/ML clinical decision support tools.What sets Purti apart is her whole-picture lens on technology adoption. She starts with the problem, not the technology, and believes that testing without measurement rarely survives the pilot. Getting to real scale means thinking through people, process, and organizational readiness together, not as an afterthought.She has mentored startups through Singularity University Labs, the UCSF Entrepreneurship Center, and HealthTech Capital. Purti holds a Master of Science in Biotechnology from Georgetown University and is based in the San Francisco Bay Area.Like this episode? Please subscribe and share!iTunes | Spotify | Overcast | iHeartRadio | AmazonConnect with the OWA:Website | LinkedIn | Instagram | Facebook

Kortney and Dr. Payel Gupta are joined by Tamara Hubbard, MA, LCPC, a licensed clinical professional counselor and food-allergy parent. Together, they dig into what food allergy anxiety actually looks like in teenagers, why some teens take more risks as they get older, and what parents can do to support their teens without making things worse. What we cover in this episode is about food allergy anxiety in teens: What makes teenagers a high-risk group for food allergy reactions. Independence is increasing at the exact same time parental oversight is decreasing, and that combination creates real safety concerns. What food allergy risk-taking actually looks like. It is not always what parents expect, and some of it is just teens figuring out how to belong. Food allergy social anxiety is its own distinct experience. The fear of looking different, being a burden, or standing out can drive behavior just as much as the fear of a reaction. Why parental anxiety matters more than most parents realize. The way parents talk about food allergies often directly affects how teens handle them. How to build confidence and ownership in your teen. What to do when a teen is either too anxious or not anxious enough. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

How CD38, PARP, and Leaky Gut Are Destroying Your NAD Levels | Dr. Andrew Salzman Your NAD is being drained by two hidden enzymes, your gut may be the starting point of every aging process in your body, and creatine does something to your mitochondria that has nothing to do with muscle. This episode rewrites what you thought you knew about longevity, anti-aging biology, and how your body actually produces and delivers energy at the cellular level. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR -Explore all of Wonderfeel's products at: getwonderfeel.com/dave They are gifting a complimentary 7-day Youngr™ supply (mini pouch) with every order across any of their products. The code will be DAVE, and the campaign will be active through June 6th. Host Dave Asprey sits down with Dr. Andrew Salzman, a physician, inventor, and biomedical entrepreneur with more than 30 years of experience in drug discovery and development. An alumnus of Harvard Medical School, Yale University, and Columbia University, Dr. Salzman has authored more than 170 scientific publications and holds 50 patents. He invented the original clinical-stage PARP-1 inhibitor, leading to the world's first clinical treatment for raising NAD levels and fighting cancers caused by the BRCA1 and BRCA2 genes. Genentech licensed his breakthrough technology for $600 million. His research into gastrointestinal microbiota, autoimmune disease, oxidative stress, and mitochondrial ATP production now forms the foundation of how millions of patients get treated worldwide. Dr. Salzman names the two biggest NAD drains in your body, CD38 and PARP, and explains why taking NMN or NR alone is like filling a bathtub with the drain wide open. He breaks down the formulation science behind pairing NAD precursors with CD38 blockers like hydroxytyrosol alongside PARP-reducing antioxidants like ergothioneine, and delivers a paradigm-shifting explanation of creatine as an energy distribution network inside your cells. Rather than a simple muscle supplement, creatine acts as a high-speed ATP shuttle that carries energy from your mitochondria to the precise location and moment your brain, gut, and heart need it most. You'll Learn: Why NAD declines with age and which two enzymes are primarily responsible for draining it How CD38 rises with inflammation rather than NAD levels, and what that means for your supplement strategy Why creatine is one of the most underrated anti-aging and brain optimization supplements available How creatine functions as a spatial and temporal energy delivery network for your brain, gut, and heart Why the gut may be the origin point of the entire aging process and how that cascade unfolds decade by decade How leaky gut drives systemic inflammation, crashes NAD, and accelerates biological aging throughout the body What controls tight junction integrity and how ATP, butyrate, creatine, and fasting all play a role Why most creatine supplements fail to absorb properly and what to look for in a high-quality source How to rebuild your microbiome in three to four weeks through diet alone, without antibiotics Why walking immediately after a meal may be doing more harm than good to your gut lining Thank you to our sponsors! - Screenfit | Get your at-home eye training program for 40% off using code DAVE at https://www.screenfit.com/dave. - KILLSwitch | If you're ready for the best sleep of your life, order now at https://www.switchsupplements.com/and use code DAVE for 20% off - Pique | Go to Piquelife.com/dave for 20% off. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Dr. Andrew Salzman, NAD depletion, CD38 inhibition, PARP inhibition, NMN supplements, creatine ATP shuttle, leaky gut aging, tight junction integrity, inflammaging, lipopolysaccharide gut, flagellin toxin, butyrate gut healing, ergothioneine, hydroxytyrosol, peroxynitrite, superoxide mitochondria, creatine energy distribution, gut origin of aging, NAD bathtub analogy, BRCA PARP inhibitor, Wonderfeel, creatine monohydrate, intestinal permeability, microbiome butyrate, selective digestive decontamination, TMAO nitric oxide Resources: • Explore all of Wonderfeel's products at: getwonderfeel.com/dave • Order Youngr™: getwonderfeel.com/dave• Order ChocoCreatin™: getwonderfeel.com/dave• Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 01:12 – Introduction & BRCA Background 02:19 – DNA Damage & PARP 04:38 – Free Radicals & Oxidative Stress 11:37 – NAD & Antioxidant Defense 12:34 – CD38 & NAD Depletion 23:31 – The Gut-Aging Hypothesis 30:05 – ATP, Creatine & Energy Distribution 36:41 – Creatine as Energy Shuttle 51:09 – Microbiome & Gut Repair 59:21 – TMAO & Nitric Oxide Interference 1:03:52 – Flagellin & Gut Inflammation Research 1:09:45 – FDA & Pharmaceutical Incentives 1:16:05 – Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Quita Highsmith is the VP of population health at Genentech, but more importantly, she's a friend of The MM+M Podcast. In her third appearance on the show, she discusses Genentech's All Eyes on DME campaign featuring comedian Damon Wayans. Launched this spring, All Eyes on DME is the drugmaker's pop culture-focused way to talk about a condition in diabetic macular edema that is both often overlooked and disproportionately impacts patients of color.  Additionally, Highsmith reflects on her decades working in healthcare and why the work doesn't stop for her or Genentech.  And for our Trends segment, we're talking with our editor-at-large Steve Madden about his time in Las Vegas covering the Enhanced Games and what it means for medical marketers. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fredric Marshall spent decades helping companies including Apple, Pfizer, and Genentech solve problems in sales effectiveness, product launches, and organizational change. In this discussion, he explains why he views sales and leadership primarily as change management challenges: helping people move from where they are to where they want to be. The conversation centers on several practical ideas that shape long-term performance. Marshall argues that strong systems reduce stress because "the system is carrying the load, not you as a person or the team." He explains why high-performing people consistently invest in infrastructure, technology, and environments that remove friction and preserve attention for higher-value work. The episode also explores Marshall's "Super Eight" framework, which includes the neural net, biological health, relationships, systems, assets, and contribution. One of the central themes is that attention shapes outcomes. "Whatever you feed [neural nets], they get better at," he explains, arguing for greater discipline around information intake, habits, and social environments. Other insights from the discussion include: • Why emotionally intelligent and externally focused people often elevate entire organizations • How successful professionals balance initiative with responsiveness rather than operating in constant reaction mode • Why many entrepreneurs underestimate the value of their own time and capabilities • How journaling, repetition, and evidence gathering can gradually replace limiting beliefs • Why wealth creation often depends on investing simultaneously in productive assets and personal capability Marshall also shares research from his work studying top performers, identifying three recurring characteristics: action orientation, external focus, and the ability to question assumptions others accept too easily. The discussion is ultimately about building a life and career intentionally: curating what enters your attention, surrounding yourself with the right people, and constructing systems that support the future you are trying to create. Get Fredric's book, Thrive: The Antidote to Future Shock, here: https://tinyurl.com/smn4u5ts Claim your free gift: Free gift #1 McKinsey & BCG winning resume www.FIRMSconsulting.com/resumePDF Free gift #2 Breakthrough Decisions Guide with 25 AI Prompts www.FIRMSconsulting.com/decisions Free gift #3 Five Reasons Why People Ignore Somebody www.FIRMSconsulting.com/owntheroom Free gift #4 Access episode 1 from Build a Consulting Firm, Level 1 www.FIRMSconsulting.com/build Free gift #5 The Overall Approach used in well-managed strategy studies www.FIRMSconsulting.com/OverallApproach Free gift #6 Get a copy of Nine Leaders in Action, a book we co-authored with some of our clients: www.FIRMSconsulting.com/gift

Sponsored by Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation. Intended for US Audiences. This information is for general purposes only and is not a substitute for consulting your healthcare provider about food allergy treatment. Dr. Ari Zelig has been financially compensated by Genentech and Novartis for his participation in this episode. Today, I'm joined by Dr. Ari Zelig, a board-certified allergist and immunologist to unpack what's really happening when it comes to food allergies - and why so many more people are dealing with them today. If you are navigating food allergies, or if you've ever wondered if what you're experiencing might be more than just a sensitivity, this episode features an informative discussion on these topics! In this episode, we dive into the reality of living with food allergies, from the day-to-day challenges that families carry to the misconceptions that still exist around what an allergic reaction to food actually looks like. Dr. Zelig breaks down IgE-mediated food allergies, what's happening in the body during a reaction, and why early exposure guidelines for kids have changed. Plus, we discuss a treatment option, XOLAIR (omalizumab), an FDA-approved prescription medication for subcutaneous use that can help reduce allergic reactions to multiple foods that may occur after accidental exposure in people with IgE-mediated food allergies one year of age and up. While taking XOLAIR you should continue to avoid all foods to which you are allergic. If you or a loved one has been diagnosed with food allergies, talk to your allergist and ask about XOLAIR. You can also find more information at XOLAIR.com. XOLAIR is one of several available treatment options for IgE-mediated food allergy and it may not be appropriate for all patients. What is XOLAIR?XOLAIR®(omalizumab) for subcutaneous use is an injectable prescription medicine used to treat food allergy in people 1 year of age and older to reduce allergic reactions that may occur after accidentally eating one or more foods to which you are allergic. While taking XOLAIR you should continue to avoid all foods to which you are allergic. It is not known if XOLAIR is safe and effective in people with food allergy under 1 year of age. XOLAIR should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. What is the most important information I should know about XOLAIR?Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:· wheezing, shortness of breath, cough, chest tightness, or trouble breathing· low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”· flushing, itching, hives, or feeling warm· swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction. Please listen to the Important Safety Information throughout and stay tuned for additional safety information at the end of this podcast. See full Prescribing Information, including Medication Guide, at bit.ly/XOLPI. This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode. Produced by Dear Media M-US-00032583(v1.0) 5/26See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Some of the most powerful shifts in leadership come from seeing something that's been there all along, but never fully acted on.   On this episode of The Unlock Moment, I am joined by Christine Barnes, executive coach, UC Berkeley lecturer, and author of Inclusionable: Transform How You Lead and Elevate Your Team's Performance ... and her story is a brilliant example of exactly that.   Christine has spent her career inside some of the world's most complex organisations, from IBM to Oracle, Roche to Genentech, helping leaders navigate change and build capability. But it was her doctoral research - begun at an age when most of her peers were thinking about retirement - that crystallised what she had been observing for decades: that despite billions spent on diversity hiring, too many people still look up in their organisations and see nobody like them.   In this conversation, we explore why most leaders can't actually distinguish between diversity and inclusion, how Christine's own biases showed up in the middle of a research interview, and why outsourcing inclusion to DEI experts, however essential they are, lets leaders off the hook.   This is a conversation about self-awareness, accountability, and the simple but transformative idea that inclusion isn't a nice-to-have. It's your most underused leadership strategy. The Unlock Moment is hosted by Dr Gary Crotaz, PhD — master interviewer, executive coach and author. Downloaded in over 140 countries. Sign up to The Unlock Moment newsletter at https://tinyurl.com/ywhdaazp Find out more at https://garycrotaz.com and https://theunlockmoment.com Also discover his other podcasts, The Box of Keys and Unlock Your Leadership. Follow, subscribe and leave a review wherever you get your podcasts — and connect with Dr Gary on LinkedIn for more leadership insights. Part of The Unlock Moment podcast family.

Food allergy anxiety in kids is real, and it does not always look like fear. It can show up as tantrums, clinginess, control-seeking behaviors, or a child who refuses to eat at a restaurant. Child life specialist and therapist Kelsey Mora joins Kortney and Dr. Payel Gupta to unpack what is really going on.  What we cover in our episode about managing anxiety in kids Food allergy anxiety does not always look like anxiety. Tantrums, clinginess, and control-seeking behaviors can all be signs that a child is struggling. Language matters from the start. How parents explain food allergies to young children can build confidence or quietly reinforce fear. Separation anxiety and food allergies are connected. Dependence on parents can make it harder for kids to navigate school, parties, and social situations on their own. Practicing independence at home builds real-world skills. Exposure to allergens in a safe home environment teaches confidence and communication skills kids need everywhere else. Passing parental anxiety onto kids. Co-regulation starts with the caregiver, when parents are anxious, kids have a harder time calming down. Helpful resources Food allergy anxiety information from Allergy & Asthma Network Kelsey's practice and services: childlifetherapist.com  Kelsey's workbooks and resources: themethodworkbooks.com  *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn't mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United's Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Chronic lymphocytic leukemia (CLL) Clinical Trial Support Center Minimal/measurable residual disease (MRD) Patti Robinson Kaufmann First Connection ® program Online Chat Patient Community Support groups Caregiver support Lessons in Blood Cancer Video: CLL Shared Decision Making in Chronic Leukemias interactive program CLL Society Patient Power Additional Blood Cancer United Support Resources: Information Specialists Financial support Free Nutrition Consultations Free telephone/web patient programs Free booklets Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

Mia Silverman, food allergy advocate, joins us to talk about the real emotional and practical side of dating with food allergies. From what the research says about kissing risks to setting boundaries to why your allergies might actually be the best filter you have. What we cover in this episode about dating with food allergies When to tell someone about your food allergies. Mia shares why she brings up her allergies early and how she works it into her dating app profile without making it a big deal. Fear of rejection. Mia opens up about being ghosted and bullied, and how she learned to reframe rejection as a filter rather than a failure. The risks of kissing with food allergies. Dr. Gupta breaks down what the research actually says about allergens in saliva and what your partner can do to reduce the risk. Intimacy beyond kissing. From latex-free condoms to body fluids, Dr. Gupta covers what food allergy patients need to know about being safely intimate with a partner. Date ideas and setting boundaries. Mia shares practical tips for early dates, setting food-allergy rules, and keeping the conversation open without making it feel overwhelming. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

In this podcast, Greg Voisen sits down with Dr. Sheila Gujrathi, a powerhouse physician and biotech entrepreneur who reached the top of the corporate ladder only to find an "inner glass ceiling" made of fear. Despite an elite career at McKinsey and Genentech, Sheila realized her greatest battles were internal. In this episode, she breaks down the roadmap from her book, The Mirror Effect: A Transformative Approach to Growth for the Next Generation of Female Leaders, revealing how high-achievers can dismantle the hidden fears that sabotage their success. If you've ever felt like an impostor while winning, this conversation will show you how to finally flip the script.

In this episode, Michele Lamoureux sits down with Fredric Marshall, a leading expert in change management, human behavior, and helping people navigate uncertainty with confidence. Over the course of his career, Fred has worked with organizations like Apple, Pfizer, and Genentech, helping teams adapt, grow, and lead through change. But this conversation goes beyond corporate performance. Fred shares why the tools for resilience, adaptability, and growth are not reserved for high achievers or executives—they're essential skills for anyone facing change, uncertainty, overwhelm, or anxiety about the future. Drawing from decades of research and experience training more than 130,000 people across fourteen countries, Fred explains how people can move from fear and overwhelm to clarity, agency, and momentum in a rapidly changing world. We also dive into his book, THRIVE: The Antidote to Future Shock, and explore practical ways people can stay grounded and hopeful during times of disruption.   RESOURCES MENTIONED Join The Newsletter Subscribe on YouTube Follow on APPLE PODCASTS Follow on SPOTIFY PODCASTS Book: Thrive: The Antidote to Future Shock Website: https://thrivefutureyou.com/     *The Good Life with Michele Lamoureux podcast and content provided by Michele Lamoureux is for educational and entertainment purposes only. It does NOT constitute medical, mental health, professional, personal, or any kind of advice or serve as a substitute for such advice. The use of information on this podcast or materials linked from this podcast or website is at the user's own risk. Always consult a qualified healthcare or trusted provider for any decisions regarding your health and wellbeing. This episode may contain affiliate links.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

In this podcast, Greg Voisen sits down with Dr. Sheila Gujrathi, a powerhouse physician and biotech entrepreneur who reached the top of the corporate ladder only to find an "inner glass ceiling" made of fear. Despite an elite career at McKinsey and Genentech, Sheila realized her greatest battles were internal. In this episode, she breaks down the roadmap from her book, The Mirror Effect: A Transformative Approach to Growth for the Next Generation of Female Leaders, revealing how high-achievers can dismantle the hidden fears that sabotage their success. If you've ever felt like an impostor while winning, this conversation will show you how to finally flip the script.

On this week's Tech Nation, we celebrate the 50th anniversary of the first biotech company to go public, Genentech. Moira speaks with CEO Ashley Magargee about the company's journey since its founding 50 years ago, and where they're going next. Then, we remember the life of the late Dr. Craig Venter, whose efforts catalysed the race to decode the first human genome.

Fred Marshall is a pioneer in identifying the behavioral patterns of top performers and scaling them across global organizations. Having worked with companies like Apple, Pfizer, and Genentech, Fred has trained over 130,000 professionals in 14+ countries and helped launch dozens of biopharma brands generating billions in revenue. In this episode, he shares how entrepreneurs can think strategically about growth, innovation, and building businesses that actually work. On this episode we talk about: Fred's early entrepreneurial experiments and what they taught him about scaling Why combining fun and work leads to better long-term success The “Uncle Bill strategy” for gaining experience before starting a business How unit economics determine whether a business succeeds or fails Leveraging AI, delegation, and systems to scale beyond yourself Top 3 Takeaways If your unit economics don't work, your business doesn't work—no matter how great the product is. Work for others strategically to learn the model, then improve and build your own version. The key to scaling is shifting from “How can I do this?” to “How can this get done?” Notable Quotes “Instead of asking how can I do this, ask how can this get done.” “If you're not enjoying your work, you should rethink what you're doing—this is most of your life.” “Every bit of knowledge is useful—you just never know when it will pay off.” Connect with Fred Marshall: LinkedIn: https://www.linkedin.com/in/fredric-marshall-1984bb/ Instagram: https://www.instagram.com/officialfredricmarshall/ Other: https://thrivefutureyou.com  Travis Makes Money is made possible by High Level – the All-In-One Sales & Marketing Platform built for agencies, by an agency.  Capture leads, nurture them, and close more deals—all from one powerful platform.  Get an extended free trial at gohighlevel.com/travis Learn more about your ad choices. Visit megaphone.fm/adchoices

When a child is diagnosed with a food allergy, one of the first things many parents wonder is, "Did I do something wrong?" and "Did I cause my child's food allergy?" You question if it was something you ate or didn't eat during pregnancy, whether you breastfed long enough, or if you introduced foods too late. The guilt is real, and it is incredibly common. Kortney and Dr. Payel Gupta sit down with Dr. Joanne Moreau, a board-certified allergist and immunologist, to unpack exactly how food allergies develop, and why no parent should carry the weight of blame. What we cover in this episode about food allergy development and parent guilt How food allergies develop. The immune system, genetics, and environment all play a role, and science is still uncovering why. Food allergy genetics and family history. A parent with asthma, eczema, or hay fever raises a child's risk, even without a food allergy themselves. Pregnancy diet, breastfeeding, and food allergy. No conclusive evidence links what a mother eats during pregnancy, or whether she breastfeeds, to whether a child develops food allergies. Eczema and food allergy. Cracked or inflamed skin lets food proteins in before the gut can build tolerance, which can trigger sensitization. Early allergen introduction. Introducing allergenic foods between 4 and 6 months of age, and keeping them in the diet consistently, is one of the best tools we have. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Genentech and Kaléo for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.